Download PDF
Klin Monbl Augenheilkd 2015; 232(5): 641-646
DOI: 10.1055/s-0035-1545939
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Allogene Blutstammzelltransplantation – ein Überblick

Allogeneic Haematopoietic Stem Cell Transplantation – An Overview
U. Holtick
Klinik I für Innere Medizin, Uniklinik Köln
,
J. M. Chemnitz
Klinik I für Innere Medizin, Uniklinik Köln
,
M. Hallek
Klinik I für Innere Medizin, Uniklinik Köln
,
C. Scheid
Klinik I für Innere Medizin, Uniklinik Köln
› Author Affiliations
Further Information

Publication History

eingereicht 02 February 2015

akzeptiert 27 March 2015

Publication Date:
19 May 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die allogene Blutstammzell- oder Knochenmarktransplantation ist eine effektive kurative Therapieoption für chemotherapierefraktäre oder rezidivierte hämatologische Neoplasien wie Leukämien und Lymphome. Nach einer Vorbehandlung mittels Chemotherapie mit oder ohne Ganzkörperbestrahlung werden Spenderzellen zur Rekonstitution der Hämatopoese verabreicht. Diese Spenderzellen üben einen über den Effekt von Chemotherapie hinausgehenden Immuneffekt zur Kontrolle oder Eradikation der Grunderkrankung aus. Einhergehend mit diesem sog. Transplantat-versus-Tumor-Effekt (graft-versus-tumor effect, GvT) tritt häufig eine akute und/oder chronische Transplantat-gegen-Wirt-Erkrankung auf (graft-versus-host disease, GvHD), die substanziell die Mortalität und Morbidität nach Transplantation mitbestimmt. Die Balance zwischen GvHD und GvT mittels verschiedener Parameter wie Spenderauswahl, Stammzellquelle, Konditionierung, Immunerholung und Immunsuppression stellt die Herausforderung für die allogene Stammzelltransplantation dar.

Abstract

Allogeneic haematopoietic stem cell transplantation is an effective treatment option for chemotherapy-refractory or relapsed haematological malignancies such as leukaemias and lymphomas. After conditioning with chemotherapy with or without total body irradiation, donor cells are infused to reconstitute haematopoiesis. Donor-derived immune cells induce immune reactions to control or eradicate the underlying disease, thereby going beyond the effect of chemotherapy. This graft-versus-tumour effect (GvT) is often accompanied by detrimental graft-versus-host reactions (graft-versus-host disease, GvHD), which substantially influence the mortality and morbidity after transplantation. The balance between GvHD and GvT, implementing various parameters such as donor selection, stem cell source, conditioning, immune reconstitution and immunosuppressive regimens, represents the challenge in the field of allogeneic stem cell transplantation.

Schlüsselwörter

allogene Blutstammzelltransplantation - Graft-versus-Host-Erkrankung - Graft-versus-Tumor-Effekt

Key words

allogeneic haematopoietic stem cell transplantation - graft-versus-host disease - graft-versus-tumour effect
 

  • Literatur

  • 1 Deutsches Register für Stammzelltransplantationen (DRST). DRST Jahresbericht 2013.. Im Internet: http://www.drst.de/download/jb2013.pdf Stand: 27.01.2015
    PubMedGoogle Scholar
  • 2 Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-1475
    CrossrefPubMedGoogle Scholar
  • 3 Vaughan W, Seshadri T, Bridges M et al. The principles and overview of autologous hematopoietic stem cell transplantation. Cancer Treat Res 2009; 144: 23-45
    PubMedGoogle Scholar
  • 4 Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389
    CrossrefPubMedGoogle Scholar
  • 5 Thomas ED. A History of Bone Marrow Transplantation. In: Blume KF, Forman SJ, Appelbaum FR, eds. Thomasʼ Hematopoietic Cell Transplantation. 3rd ed. Malden: Blackwell Publishing; 2004: 3-8
    Google Scholar
  • 6 Dausset J, Brecy H. Identical nature of the leucocyte antigens detectable in monozygotic twins by means of immune iso-leuco-agglutinins. Nature 1957; 180: 1430
    PubMedGoogle Scholar
  • 7 Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930
    CrossrefPubMedGoogle Scholar
  • 8 Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood 2013; 122: 1863-1872
    CrossrefPubMedGoogle Scholar
  • 9 Gratwohl A, Baldomero H, Gratwohl M et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013; 98: 1282-1290
    CrossrefPubMedGoogle Scholar
  • 10 Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65
    CrossrefPubMedGoogle Scholar
  • 11 Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122: 491-498
    CrossrefPubMedGoogle Scholar
  • 12 Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 124: 334-343
    CrossrefPubMedGoogle Scholar
  • 13 Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 1957; 3: 241-252
    CrossrefPubMedGoogle Scholar
  • 14 Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073
    CrossrefPubMedGoogle Scholar
  • 15 Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562
    PubMedGoogle Scholar
  • 16 Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465
    PubMedGoogle Scholar
  • 17 Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123-137
    PubMedGoogle Scholar
  • 18 Holtick U, Marshall SR, OʼBrien SG et al. Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia. Blood 2007; 110: 4622-4623
    CrossrefPubMedGoogle Scholar
  • 19 Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014; 124: 344-353
    CrossrefPubMedGoogle Scholar
  • 20 Storb R, Gyurkocza B, Storer BE et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31: 1530-1538
    CrossrefPubMedGoogle Scholar
  • 21 Cantu-Rodriguez OG, Gutierrez-Aguirre CH, Jaime-Perez JC et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol 2011; 87: 521-530
    CrossrefPubMedGoogle Scholar
  • 22 Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919
    CrossrefPubMedGoogle Scholar
  • 23 Sorror ML, Sandmaier BM, Storer BE et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874-1883
    CrossrefPubMedGoogle Scholar
  • 24 Billingham RE. The Biology of Graft-Versus-Host Reactions. New York: New York Academic Press; 1966
    Google Scholar
  • 25 Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002; 62: 879-889
    CrossrefPubMedGoogle Scholar
  • 26 Wolf D, von Lilienfeld-Toal M, Wolf AM et al. Novel treatment concepts for graft-versus-host disease. Blood 2012; 119: 16-25
    CrossrefPubMedGoogle Scholar
  • 27 Finke J, Bethge WA, Schmoor C et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864
    CrossrefPubMedGoogle Scholar
  • 28 Ferrara JL, Levine JE, Reddy P et al. Graft-versus-host disease. Lancet 2009; 373: 1550-1561
    CrossrefPubMedGoogle Scholar
  • 29 Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014; 124: 374-384
    CrossrefPubMedGoogle Scholar
  • 30 Wolff D, Bertz H, Greinix H et al. The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch Arztebl Int 2011; 108: 732-740
    PubMedGoogle Scholar
  • 31 Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015; 125: 606-615
    CrossrefPubMedGoogle Scholar
  • 32 Wood WA, Chai X, Weisdorf D et al. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant 2013; 48: 1429-1436
    CrossrefPubMedGoogle Scholar
  • 33 Hilgendorf I, Greinix H, Halter JP et al. Long-term follow-up after allogeneic stem cell transplantation. Dtsch Arztebl Int 2015; 112: 51-58
    PubMedGoogle Scholar